Newly Discovered Cutting-Edge Triple Combination Cystic Fibrosis Therapy: A Systematic Review

A cystic fibrosis (CF) transmembrane conductor regulator (CFTR) gene modulating triple therapy combining elexacaftor-tezacaftor-ivacaftor (Trikafta) has been recently discovered. Its approval by the Food and Drug Administration (FDA) in 2019 has expanded the target therapy group to individuals aged...

Descripción completa

Detalles Bibliográficos
Autores principales: Dawood, Sarah N, Rabih, Ahmad M, Niaj, Ahmad, Raman, Aishwarya, Uprety, Manish, Calero, Maria Jose, Villanueva, Maria Resah B, Joshaghani, Narges, Villa, Nicole, Badla, Omar, Goit, Raman, Saddik, Samia E, Mohammed, Lubna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9583755/
https://www.ncbi.nlm.nih.gov/pubmed/36284811
http://dx.doi.org/10.7759/cureus.29359

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9583755/
https://www.ncbi.nlm.nih.gov/pubmed/36284811
http://dx.doi.org/10.7759/cureus.29359

Ejemplares similares